Cardiovascular Outcome Studies in Diabetes Drugs Finally Arrive
For more of our ESC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the...
View ArticleWhat You Need to Know About IMPROVE-IT
The IMPROVE-IT trial will be big news when its results are finally presented on November 17 during the annual meeting of the American Heart Association. The results of the trial — underway for nearly a...
View ArticleCardiovascular Outcomes with Sitagliptin: No Better or Worse Than...
Late Monday afternoon, Merck released the top line results of TECOS, the cardiovascular outcomes trial with its diabetes drug sitagliptin (Januvia). The company said that the trial “achieved its...
View Article
More Pages to Explore .....
